Abstract
Background and Objectives
Lobeglitazone is a recently approved peroxisome proliferator-activated receptor-γ agonist for the treatment of type 2 diabetes mellitus in Korea. The purpose of this study was to investigate the pharmacokinetic properties of lobeglitazone in healthy females and to compare these with historical data in healthy males.
Methods
This study was designed as a block-randomized, double-blind, placebo-controlled, parallel-group study. A single 2 or 4 mg oral dose of lobeglitazone or a placebo was randomly administered to 22 female subjects, and pharmacokinetic blood samples were obtained after dosing. Pharmacokinetic parameters were calculated by a non-compartmental method, and the results were compared with those previously obtained from male subjects. Tolerability was assessed by clinical and laboratory parameters.
Results
During the study, a total of 28 adverse events (AEs) were observed in the lobeglitazone group (n = 16) and nine AEs in the placebo group (n = 6). Serious AEs or significant clinical changes were not observed. After oral administration, lobeglitazone was rapidly absorbed with the time to maximum plasma concentration (t max) ranging from 0.5 to 4.0 h. The mean (standard deviation) maximum plasma concentration (C max) and area under the plasma concentration–time curve from time zero to infinity (AUC∞) for the 2 mg dose were 214.8 (56.4) µg/L and 2,251.3 (721.2) µg·h/L, respectively, and the corresponding values for the 4 mg dose were 310.0 (47.8) µg/L and 6,942.6 (1,778.9) µg·h/L, respectively. The ratios (95 % CIs) for the geometric means (female/male) of the C max and AUC∞ were 1.23 (0.89–1.69) and 1.11 (0.73–1.68), respectively (2 mg), and 1.28 (1.01–1.63) and 2.36 (1.60–3.47), respectively (4 mg).
Conclusion
Lobeglitazone was well-tolerated in healthy females. There was no sex difference for systemic lobeglitazone exposure at a 2 mg dose; however, female subjects showed greater systemic exposure than males after the administration of 4 mg of lobeglitazone. In spite of the pharmacokinetic difference, dose adjustment based on sex alone is not needed in clinical use because therapy should be individualized for each patient to achieve glycemic control.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Harold YJ, editor. Insulin resistance in type 2 diabetes. Oxford: Blackwell; 2003.
Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 2001;24(12):873–88.
Kostapanos MS, Elisaf MS, Mikhailidis DP. Pioglitazone and cancer: angel or demon? Curr Pharm Des. 2013;19(27):4913–29.
Palee S, Chattipakorn S, Phrommintikul A, et al. PPARgamma activator, rosiglitazone: is it beneficial or harmful to the cardiovascular system? World J Cardiol. 2011;3(5):144–52.
FDA News Release: FDA requires removal of certain restrictions on the diabetes drug Avandia. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm. Accessed 20 Dec 2013.
Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270(22):12953–6.
Belfiore A, Genua M, Malaguarnera R. PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer. PPAR Res. 2009;2009:830501.
Lee JH, Woo YA, Hwang IC, et al. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. J Pharm Biomed Anal. 2009;50(5):872–7.
Kim BY, Ahn JB, Lee HW, et al. Synthesis and antihyperglycemic activity of erythrose, ribose and substituted pyrrolidine containing thiazolidinedione derivatives. Chem Pharm Bull (Tokyo). 2003;51(3):276–85.
Kim BY, Ahn JB, Lee HW, et al. Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur J Med Chem. 2004;39(5):433–47.
Lee HW, Ahn JB, Kang SK, et al. Process development and scale-up of PRAR alpha/gamma dual agonist lobeglitazone sulfate (CKD-501). Org Process Res Dev. 2007;11(2):190–9.
Sauerberg P, Bury PS, Mogensen JP, et al. Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. J Med Chem. 2003;46(23):4883–94.
Kim JW, Kim JR, Yi S, et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther. 2011;33(11):1819–30.
Fujita Y, Yamada Y, Kusama M, et al. Sex differences in the pharmacokinetics of pioglitazone in rats. Comp Biochem Physiol C Toxicol Pharmacol. 2003;136(1):85–94.
Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2000;22(10):1151–68.
Kim B, Shin HS, Kim JR, et al. Quantitative and qualitative analysis of CKD-501, lobeglitazone, in human plasma and urine using LC–MS/MS and its application to a pharmacokinetic study. Chromatographia. 2012;75(11–12):671–7.
Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther. 2007;81(2):298–304.
Lee HW, Kim BY, Ahn JB, et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem. 2005;40(9):862–74.
Chawla A, Schwarz EJ, Dimaculangan DD, et al. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 1994;135(2):798–800.
Kuzuya T, Kosaka K, Akanuma Y, et al. Baseline factors affecting the efficacy of troglitazone on plasma glucose in Japanese patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1998;41(2):121–9.
Gandhi M, Aweeka F, Greenblatt RM, et al. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499–523.
Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 2000;23(8):1067–71.
Malcolm R, Tozer TN, editors. Clinical pharmacokinetics and pharmacodynamics. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
Transon C, Lecoeur S, Leemann T, et al. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol. 1996;51(1):79–85.
Actos (pioglitazone) [prescribing information]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021073s043s044lbl.pdf. Accessed 20 Dec 2013.
Acknowledgments
This study was sponsored by Chong Kun Dang Pharmaceutical Co., Seoul, Korea, and was designed and conducted by qualified investigators from the Department of Clinical Pharmacology and Therapeutics at Seoul National University Hospital. The sponsor did not play any major role in the design, the data collection, or the analysis of the study; the sponsor only contributed to the initial study design and the review of this article. Chin Kim is an employee of Chong Kun Dang Pharmaceutical Co. Ltd., Seoul, Korea. The other authors have no conflicts of interest to disclose. M.K. Park, T.E. Kim and J.W. Kim were supported by a training program grant from the Korea Healthcare Technology Research and Development Project, the Ministry for Health and Welfare of the Republic of Korea (A070001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, M.K., Kim, TE., Kim, J. et al. Tolerability and Pharmacokinetics of Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor-γ Agonist, After a Single Oral Administration in Healthy Female Subjects. Clin Drug Investig 34, 467–474 (2014). https://doi.org/10.1007/s40261-014-0197-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-014-0197-y